Trial Profile
An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 Compared With Sevelamer Carbonate Followed by a Randomised Comparison of PA21 Maintenance Dose Versus PA21-Low Dose in Dialysis Patients With Hyperphosphataemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sucroferric oxyhydroxide (Primary) ; Sevelamer
- Indications Hyperphosphataemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Vifor Pharma
- 29 May 2018 Results of post-hoc analysis from both parent (NCT01324128) and extension (NCT01464190) study assessing the effects serum phosphate control and FGF-23 levels with sucroferric oxyhydraoxide and sevelamer on CKD-MBD parameters among dialysis patients who completed 1 year of treatment with sucroferric oxyhydroxide or sevelamer published in the Nephrology Dialysis Transplantation
- 01 Apr 2017 Results (n=213) comparing efficacy and safety of sucroferric oxyhydroxide with sevelamer hydrochloride published in the Nephrology.
- 23 Feb 2017 Results (n=1055) of both parent and extension study assessing one year efficacy and safety published in the Nephrology Dialysis Transplantation.